FDA panel rejects Boehringer Ingelheim's sexual desire drug
This article was originally published in Scrip
Executive Summary
The US FDA's advisory committee for reproductive health drugs unanimously recommended on 18 June that the agency reject Boehringer Ingelheim's NDA to market flibanserin as a treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women.